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Kinase Suppressor of Ras (KSR) is a molecular scaf-
fold that interacts with the core kinase components
of the ERK cascade, Raf, MEK, and ERK and provides
spatial and temporal regulation of Ras-dependent ERK
cascade signaling. In this report, we identify the hetero-
tetrameric protein kinase, casein kinase 2 (CK2), as a
new KSR1-binding partner. Moreover, we find that
the KSR1/CK2 interaction is required for KSR1 to max-
imally facilitate ERK cascade signaling and contrib-
utes to the regulation of Raf kinase activity. Binding
of the CK2 holoenzyme is constitutive and requires
the basic surface region of the KSR1 atypical C1
domain. Loss of CK2 binding does not alter the
membrane translocation of KSR1 or its interaction
with ERK cascade components; however, disruption
of the KSR1/CK2 interaction or inhibition of CK2 activ-
ity significantly reduces the growth-factor-induced
phosphorylation of C-Raf and B-Raf on the activating
serine site in the negative-charge regulatory region
(N-region). This decrease in Raf N-region phosphory-
lation further correlates with impaired Raf, MEK, and
ERK activation. These findings identify CK2 as a novel
component of the KSR1 scaffolding complex that facil-
itates ERK cascade signaling by functioning as a Raf
family N-Region kinase.
Results and Discussion
CK2 Is a Component of the KSR1
Scaffolding Complex
The KSR1 scaffold translocates from the cytosol to the
plasma membrane upon Ras activation and coordinates
the assembly of a multiprotein complex that colocalizes
MEK with its upstream activator Raf and downstream
target ERK and thereby promotes signal transmission
between the core kinase components of the ERK cas-
cade [1, 2]. To isolate novel regulators that may impact
KSR1 function and ERK cascade signaling, we used
mass spectrometry to further characterize the proteins
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the known KSR1-interacting molecules were detected
as were peptides derived from the a, a0, and b subunits
of CK2 (see Figure S1 in the Supplemental Data available
with this article online). CK2 is a heterotetrameric serine/
threonine kinase composed of two regulatory (b) and
two catalytic (a and/or a0) subunits [3, 4]. Coimmunopre-
cipitation assays confirmed the KSR1/CK2 interaction
and demonstrated the association of endogenous
KSR1 and CK2 in mouse brain tissues (Figures 1A and
1B). Moreover, binding of the CK2 subunits was found
to be constitutive and did not change with growth-factor
treatment.
The CK2 Holoezyme Binds to the Basic Surface
Region of the KSR1 Atypical C1 Domain
By using a series of KSR1 deletion mutants to determine
the region of KSR1 required for CK2 binding, we local-
ized the CK2 interaction site to KSR1 residues 320–424,
a region encompassing the KSR1 C1 domain (Figure 1C).
CK2 did not interact with a chimeric KSR1 protein, in
which the C1 domain of KSR1 was replaced with the
closely related C1 domain from C-Raf (C1R-KSR1) and
was not detected in complexes containing the wild-
type C-Raf protein, indicating that CK2 binds selectively
to the KSR1 C1 domain (Figure 1D). Strikingly, we found
that the basic surface region, which is unique to the
KSR1 C1 domain [5], was critical for CK2 binding. Muta-
tion of lysine 360 and arginine 363 to either alanine res-
idues (KR/AA) or to glutamine and glycine residues KR/
QG (as found in the C-Raf C1 domain) abolished CK2
binding but had no effect on the association of MEK
and 14-3-3, proteins that bind to sites outside the C1 do-
main (Figure 1E). Moreover, by using bacterially-ex-
pressed, recombinant CK2 proteins, we found that the
a, a0, and b subunits were all capable of associating
with WT-KSR1 in in vitro-binding assays but showed
little to no interaction with KR/AA-KSR1 (Figure 1F).
Loss of CK2 Binding Alters the ERK Scaffolding
Activity of KSR1
The CK2 holoenzyme exhibits constitutive catalytic ac-
tivity, and an apparent consequence of the KSR1/CK2
interaction is the constitutive phosphorylation of KSR1
on S518 ([6] and Figure S2), a site contained within a con-
sensus CK2 phosphorylation motif (S/T-x-x-E/D/pY/pS/
pT [7]). To investigate the functional significance of the
KSR1/CK2 interaction, we examined KSR1 mutants de-
fective in either CK2 binding (KR/AA-KSR1) or CK2-
mediated S518 phosphorylation (S518A-KSR1) for their
ERK scaffolding activity and subcellular localization. Al-
though these mutants showed no defect in MEK or ERK
binding, KR/AA-KSR1 complexes isolated from PDGF-
treated NIH 3T3 cells contained significantly reduced
levels of activated phosphoMEK and phosphoERK in
comparison to WT- and S518-KSR1 complexes (Fig-
ure 2A). These results indicate a deficiency in the ERK
scaffolding activity of KR/AA-KSR1, and this deficiency
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180Figure 1. CK2 Is a Component of the KSR1 Scaffolding Complex
(A) Pyo-tagged WT-KSR1 was immunoprecipitated from lysates of quiescent and PDGF-treated NIH 3T3 cells, and the immune complexes were
examined by immunoblot analysis as indicated.
(B) Endogenous KSR1 was immunoprecipitated from mouse brain lysates and examined by immunoblot analysis as indicated.
(C and D) Pyo-tagged KSR1 deletion mutant proteins, WT-KSR1, WT-C-Raf, and a chimeric KSR1 protein containing the C-Raf C1 domain (C1R-
KSR1), were immunoprecipitated from lysates of transfected COS-7 cells, and the immune complexes were examined as indicated.
(E) Pyo-tagged KSR1 proteins were immunoprecipitated and examined by immunoblot analysis as indicated. Also shown are the ribbon and sur-
face charge diagrams of the KSR1 C1 domain [5] depicting the K360 and R363 residues required for CK2 binding.
(F) Affinity-immobilized recombinant CK2a, CK2a0, and CK2b were incubated with lysates containing WT- or KR/AA-KSR1 and examined for
KSR1 association by immunoblot analysis.was also observed in the Xenopus oocyte meiotic matu-
ration assay. In this system, coexpression of WT-KSR1
with RasV12 or activated receptor tyrosine kinases in-
creases the rate of MEK and ERK activation and thus
results in faster oocyte maturation [8]. However, unlike
WT- and S518A-KSR1, KR/AA-KSR1 did not accelerate
oocyte maturation in response to Tpr-MET or EGF recep-
tor activation, and oocytes expressing KR/AA-KSR1 dis-
played significantly lower levels of activated MEK and
ERK than did those expressing WT- or S518A-KSR1
(Figure 2B and Figure S3). Thus, in two different assay
systems, loss of CK2 binding impaired KSR1’s ability
to facilitate MEK and ERK activation. In contrast, despite
the constitutive phosphorylation of KSR1 on S518, muta-
tion of this site had no apparent effect in these assays,
and the biological significance of S518 phosphorylation
is currently unknown.
The translocation of KSR1 to the plasma membrane
after signal activation is critical for its scaffolding func-
tion, and this process requires the C1 domain [5, 9]. Sig-
nificantly, we found that although the KR/AA mutation in
the KSR1 C1 domain disrupts CK2 binding, it did notalter the membrane localization of KSR1 after mitogen
stimulation (Figure 2C). Moreover, cell-fractionation ex-
periments revealed that CK2 is a component of the
membrane-localized WT-KSR1 complexes (Figure 2C).
CK2 Contributes to the ERK Scaffolding Activity
of KSR1 by Functioning as a Raf N-Region
Serine Kinase
The above results indicate that the KSR1/CK2 interac-
tion is required for maximal KSR1 scaffolding activity.
However, because loss of CK2 binding does not alter
the ability of KSR1 to bind MEK and ERK or to translo-
cate to the plasma membrane in an inducible manner,
it appears that the scaffolding defect of the KR/AA-
KSR1 mutant lies upstream of MEK and might thus im-
pact Raf kinase activity. Mammalian cells contain three
Raf kinases, A-Raf, B-Raf, and C-Raf, and activation of
all three enzymes depends on the phosphorylation of
residues in two regions of the catalytic domain: the acti-
vation segment and the negative-charge regulatory re-
gion (N-region) [10, 11]. Analysis of the Raf sequences
indicated that the activating serine site in the N-region
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181Figure 2. Loss of CK2 Binding Alters the ERK Scaffolding Activity of KSR1
(A) Pyo-tagged WT-, S518A-, and KR/AA-KSR1 proteins immunoprecipitated from quiescent and PDGF-treated (5 min) NIH 3T3 cells were ex-
amined by immunoblot analysis as indicated.
(B) Stage VI Xenopus oocytes coexpressing WT EGF receptor (EGFR) and WT- or KR/AA-KSR1 were treated with EGF and scored for germinal
vesicle breakdown (GVBD) 5 hr after EGF addition. Lysates were examined by immunoblot analysis as indicated. Means of three separate ex-
periments are shown, and error bars indicate the SEM.
(C) Localization of the Pyo-tagged KSR1 proteins in quiescent and PDGF-treated NIH 3T3 cells was determined by indirect immunofluorescent
staining and cell fractionation. KSR1 proteins immunoprecipitated from membrane fractions were examined by immunoblot analysis.might be a target for CK2 phosphorylation (Figure 3A).
For C-Raf and A-Raf, this serine (C-Raf S338, A-Raf
S299) is followed at the +2/+3 positions by tyrosine res-
idues known to be phosphorylated under certain signal-
ing conditions [10–12] and, as a result, might be a poten-
tial CK2 target after the phosphorylation of these
residues. In contrast, B-Raf contains negatively charged
aspartic-acid residues at the +2/+3 positions, suggest-
ing that the B-Raf N-region serine (S446) might be a con-
stitutive CK2 target.
To determine whether the Raf kinases are CK2 sub-
strates, we performed in vitro kinase assays by using re-
combinant CK2a and affinity-purified, kinase-dead (KD)
B-Raf and C-Raf proteins (to ensure that any in vitro
phosphorylation detected could be attributed to CK2
activity and not Raf autophosphorylation). A-Raf was
not included in these experiments, given its sequence
similarity to C-Raf. As shown in Figure 3B, CK2 effi-
ciently phosphorylated KD/B-Raf but could only phos-
phorylate KD/C-Raf that had been coexpressed with
v-Src (to induce Y341 phosphorylation) or contained
an aspartic-acid residue at the 341 site. Analysis of the
labeled proteins indicated that C-Raf was phosphory-
lated on one major site, S338, whereas B-Raf was phos-
phorylated on two sites, S446 and S430, which also liesin a CK2 phosphorylation motif (Figure S4). Thus, the ac-
tivating serine site in the Raf N-region is a target of CK2
in vitro but only when a negatively-charged residue is
present at the +3 position (either an acidic amino acid
or a phosphorylated residue).
By using NIH 3T3 cells that stably express either WT-
or KR/AA-KSR1, we next investigated the contribution
of KSR1-bound CK2 to Raf N-region phosphorylation in
vivo. As shown in Figure 3C, the growth-factor-induced
phosphorylation of C-Raf at the N-region S338 site was
dramatically reduced in cells expressing KR/AA-KSR1,
whereas phosphorylation of the nearby Y341 site was
unaffected. Consistent with previous reports [10], basal
N-region phosphorylation of B-Raf S446 was elevated
in comparison to C-Raf S338. Nonetheless, PDGF treat-
ment increased B-Raf phosphoS446 levels approxi-
mately 3-fold in WT-KSR1-expressing cells but had little
effect on cells expressing KR/AA-KSR1 (Figure 3C). The
reduction in N-region serine phosphorylation also corre-
lated with a decrease in the growth-factor-induced acti-
vation of C-Raf and B-Raf in KR/AA-expressing cells
(Figure 3D). In addition, reduced C-Raf S338 and B-Raf
S446 phosphorylation was also observed when KR/AA-
KSR1 function was examined during EGF-induced Xen-
opus oocyte maturation (Figure 3E). Strikingly, B-Raf
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182Figure 3. The CK2/KSR1 Interaction Impacts the N-Region Phosphorylation of C-Raf and B-Raf
(A) The amino acid sequence surrounding the N-region activating serine site in C- and B-Raf. Also depicted is the CK2 consensus phosphory-
lation motif.
(B) The indicated Flag-tagged kinase-dead (KD) C- and B-Raf proteins and KD/C-Raf coexpressed with v-Src were affinity purified from cell ly-
sates and confirmed to be devoid of contaminating kinase activities. The purified proteins were examined by immunoblot analysis as indicated
prior to use in CK2a in vitro phosphorylation assays. Phosphorylated proteins were visualized by autoradiography after SDS-PAGE.
(C) Quiescent NIH 3T3 cells expressing WT- or KR/AA-KSR1 were left untreated or were stimulated with PDGF (5 min) prior to lysis. In some
experiments, WT-KSR1-expressing cells were pretreated for 6 hr with 60 mM TBB prior to PDGF treatment and lysis. These conditions of
TBB treatment significantly inhibited CK2 activity but did not alter cell viability or the activity of the Pak and PKC kinases. Endogenous
C- and B-Raf proteins were immunoprecipitated and examined by immunoblot analysis as indicated. KSR1 protein levels are also shown.
(D) Raf activity was measured in immune-complex kinase assays with kinase-inactive MEK as a substrate. Means of three separate experiments
are shown, and error bars indicate the SEM.
(E) Stage VI Xenopus oocytes coexpressing EGFR and WT- or KR/AA-KSR1 were treated with EGF (10 min) prior to lysis. Endogenous C- and
B-Raf proteins were immunoprecipitated and examined by immunoblot analysis as indicated. KSR1 and EGFR protein levels are also shown.phosphoS446 levels were almost undetectable in ar-
rested stage VI oocytes, and our preliminary analysis
suggests that the basal phosphorylation of B-Raf S446
can vary dramatically depending on cell type, signaling
state of the cell, and the endogenous levels of KSR1,
CK2, and B-Raf (data not shown).
To further investigate the involvement of CK2 in Raf N-
region phosphorylation, we assessed the effects of re-
ducing CK2 activity. Although we found that expression
of the CK2 subunits could be knocked down by using
RNAi, efficient depletion of CK2 resulted in a dramatic
loss of cell viability (data not shown), likely reflecting
the fact that CK2 is an essential protein kinase with
many cellular substrates [7]. However, when CK2 activity
was transiently inhibited with 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (TBB), a pronounced ef-
fect on Raf N-region phosphorylation was observed.
Pretreatment of WT-KSR1-expressing NIH 3T3 cells
with TBB significantly reduced the levels of B-Raf S446
and C-Raf S338 phosphorylation induced by PDGF
treatment, whereas C-Raf Y341 phosphorylation was
unaffected (Figure 3C).
The above findings identify CK2 as a Raf family N-re-
gion kinase. Although Pak kinases have been shown to
phosphorylate the C-Raf N-region S338 site [13–15], it
appears that the Paks are not major contributors to the
growth-factor-induced S338 phosphorylation observed
in WT-KSR1-expressing cells. By using the Pak1 autoin-
hibitory domain (PID) to suppress Pak activation [16],
we found that PID expression had no effect on C-Raf
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183Figure 4. A Novel Role for KSR1 in the C-Raf Activation Process
(A) KSR1, C-Raf, or B-Raf proteins were immunoprecipitated from quiescent and PDGF-treated WT-KSR1-expressing NIH 3T3 cells. Cell lysates
and the immune complexes were examined by immunoblot analysis as indicated.
(B) Endogenous B-Raf proteins immunoprecipitated from brain tissue extracts of WT and KSR12/2mice were examined by immunoblot analysis
as indicated.
(C) Proposed model for KSR1 in Raf kinase regulation. Growth-factor treatment induces the translocation of the Raf kinases and the KSR1 scaf-
folding complex to the plasma membrane where CK2 can function as a Raf N-region serine kinase. B-Raf S446 is a constitutive target of CK2,
whereas C-Raf requires prior phosphorylation of N-region Y341 by Src family kinases. Active Raf phosphorylates MEK, which in turn phosphor-
ylates ERK.phosphoS338 levels in EGF-treated cells expressing
WT-KSR1 and that it caused no further inhibition of
S338 phosphorylation in cells expressing the KR/AA-
KSR1 mutant (Figure S5). Interestingly, we found that
EGF treatment had only a modest effect on Pak activity
(Figure S5), and our results identifying CK2 as a Raf N-
region kinase are consistent with the previous finding
that cells contain another kinase whose ability to phos-
phorylate the S338 site is dependent on Y341 phosphor-
ylation [10, 17].
KSR1 has been shown to associate with C-Raf in
a growth-factor-inducible manner [18, 19] and, as a re-
sult, would colocalize CK2 with its potential target. Like-
wise, we found that B-Raf strongly interacts with KSR1
in growth-factor-treated KSR1-expressing NIH 3T3 cells
(Figure 4A). Endogenous complex formation between
KSR1 and B-Raf could also be detected in extracts of
mouse brain tissue (Figure 4B). Strikingly, when B-Raf
protein from WT and KSR12/2 brains was compared
[20], phosphorylation of S446 was reduced in KSR12/2
tissues (Figure 4B), providing evidence that KSR1 im-
pacts B-Raf N-region phosphorylation in vivo. Notably,
B-Raf isolated from the KSR12/2 brains was complexed
with the other mammalian KSR scaffold, KSR2 (Fig-
ure 4B), and given that KSR2 also interacts with CK2
(data not shown), it is possible that KSR2-bound CK2
may contribute to B-Raf S446 phosphorylation in the
KSR12/2 animals. Taken together, these findings iden-
tify CK2 as a biologically relevant Raf N-region kinase
and reveal a role for KSR1 in facilitating Raf kinase
activation.
Conclusions
The results presented here identify CK2 as a novel com-
ponent of the KSR1 scaffolding complex. Moreover, we
find that when KSR1 translocates to the cell surface
upon signal activation, not only does it colocalize MEK
and ERK with the Raf family kinases but it also deliversthe active CK2 holoenzyme, a kinase that contributes
to Raf activation (Figure 4C). CK2 directly phosphory-
lates the activating serine site in the N-region of B-Raf
(S446) and C-Raf (S338); however, in the case of C-
Raf, the N-region S338 site is also a target for other iden-
tified kinases, including members of the Pak and PKC
families [13–15, 21]. Given that N-region phosphoryla-
tion is required for Raf activation, it is tempting to spec-
ulate that the N-region of C-Raf has evolved such that it
can receive inputs from multiple upstream activators
and thus allow C-Raf to integrate diverse signaling stim-
uli into appropriate ERK cascade activation. Strikingly,
B-Raf and C-Raf are differentially regulated by CK2.
Phosphorylation of the C-Raf N-region S338 site re-
quires prior phosphorylation of Y341, most likely medi-
ated by Src family kinases. In contrast, because of the
acidic residues present in the B-Raf N-region, B-Raf is
a constitutive CK2 target. The B-Raf N-region serine
has been found to be more highly phosphorylated than
the corresponding C-Raf site in many cell types, sug-
gesting that CK2 might be particularly relevant for cell
signaling and oncogenic transformation involving B-
Raf. Significantly, the finding that the KSR1 scaffolding
complex contains a Raf activating kinase may help re-
solve the controversy over whether KSR1 has intrinsic
kinase activity and may provide an explanation for the
KSR1-associated Raf kinase activities that have been
detected in previous studies and that have been attrib-
uted to KSR1 itself [22–24]. Based on the results pre-
sented here together with the findings that all mamma-
lian KSR proteins lack a critical lysine residue normally
required for the phosphotransfer reaction, we would
propose that KSR1 contributes to Raf activation, not
by directly phosphorylating the kinases but rather by
localizing the Raf proteins with an upstream activating
kinase, CK2. Interestingly, a recent report examining
Ras-dependent ERK pathway activation in Drosophila
S2 cells has also indicated a kinase-independent role
for D-KSR in Raf activation [25]. In conclusion, these
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demonstrate that the KSR1 scaffold acts at multiple
points to ensure efficient activation and signal transmis-
sion through the ERK cascade’s core kinase compo-
nents—Raf, MEK, and ERK.
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ures and can be found with this article online at http://www.
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